Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market 2022 by Company, Regions, Type and Application, Forecast to 2028

  • receipt Report ID : 118923
  • calendar_today Published On: Mar, 2022
  • file_copy Pages: 156
  • list Pharmaceuticals and Healthcare
Buy @ $3500

The Paroxysmal Nocturnal Hemoglobinuria Treatment market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

According to our latest study, due to COVID-19 pandemic, the global Paroxysmal Nocturnal Hemoglobinuria Treatment market size is estimated to be worth US$ 3420.4 million in 2021 and is forecast to a readjusted size of USD 5909.6 million by 2028 with a CAGR of 8.1% during review period. Hospital accounting for % of the Paroxysmal Nocturnal Hemoglobinuria Treatment global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While ACH-4471 segment is altered to a % CAGR between 2022 and 2028.

Global key companies of Paroxysmal Nocturnal Hemoglobinuria Treatment include Achillion Pharmaceuticals Inc, Akari Therapeutics Plc, Alexion Pharmaceuticals Inc, Alnylam Pharmaceuticals Inc, and Amgen Inc, etc. In terms of revenue, the global top four players hold a share over % in 2021.

Market segmentation

Paroxysmal Nocturnal Hemoglobinuria Treatment market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type, covers

ACH-4471

ALN-CC5

ALXN-1210

AMY-101

APL-2

Others

Market segment by Application, can be divided into

Hospital

Clinic

Others

Market segment by players, this report covers

Achillion Pharmaceuticals Inc

Akari Therapeutics Plc

Alexion Pharmaceuticals Inc

Alnylam Pharmaceuticals Inc

Amgen Inc

Apellis Pharmaceuticals Inc

F. Hoffmann-La Roche Ltd

ISU ABXIS Co Ltd

Novartis AG

NovelMed Therapeutics Inc

Omeros Corp

Ra Pharmaceuticals Inc

Regeneron Pharmaceuticals Inc

Regenesance BV

Market segment by regions, regional analysis covers

North America (United States, Canada, and Mexico)

Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)

South America (Brazil, Argentina, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 12 chapters:

Chapter 1, to describe Paroxysmal Nocturnal Hemoglobinuria Treatment product scope, market overview, market opportunities, market driving force and market risks.

Chapter 2, to profile the top players of Paroxysmal Nocturnal Hemoglobinuria Treatment, with revenue, gross margin and global market share of Paroxysmal Nocturnal Hemoglobinuria Treatment from 2019 to 2022.

Chapter 3, the Paroxysmal Nocturnal Hemoglobinuria Treatment competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Paroxysmal Nocturnal Hemoglobinuria Treatment market forecast, by regions, type and application, with revenue, from 2023 to 2028.

Chapter 11 and 12, to describe Paroxysmal Nocturnal Hemoglobinuria Treatment research findings and conclusion, appendix and data source.

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

1 Market Overview

1.1 Product Overview and Scope of Paroxysmal Nocturnal Hemoglobinuria Treatment

1.2 Classification of Paroxysmal Nocturnal Hemoglobinuria Treatment by Type

1.2.1 Overview: Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type: 2017 Versus 2021 Versus 2028

1.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type in 2021

1.2.3 ACH-4471

1.2.4 ALN-CC5

1.2.5 ALXN-1210

1.2.6 AMY-101

1.2.7 APL-2

1.2.8 Others

1.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market by Application

1.3.1 Overview: Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application: 2017 Versus 2021 Versus 2028

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size & Forecast

1.5 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast by Region

1.5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2017 VS 2021 VS 2028

1.5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region, (2017-2022)

1.5.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Prospect (2017-2028)

1.5.4 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Prospect (2017-2028)

1.5.5 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Prospect (2017-2028)

1.5.6 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Prospect (2017-2028)

1.5.7 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Prospect (2017-2028)

1.6 Market Drivers, Restraints and Trends

1.6.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers

1.6.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints

1.6.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Trends Analysis

2 Company Profiles

2.1 Achillion Pharmaceuticals Inc

2.1.1 Achillion Pharmaceuticals Inc Details

2.1.2 Achillion Pharmaceuticals Inc Major Business

2.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.1.4 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.1.5 Achillion Pharmaceuticals Inc Recent Developments and Future Plans

2.2 Akari Therapeutics Plc

2.2.1 Akari Therapeutics Plc Details

2.2.2 Akari Therapeutics Plc Major Business

2.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.2.4 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.2.5 Akari Therapeutics Plc Recent Developments and Future Plans

2.3 Alexion Pharmaceuticals Inc

2.3.1 Alexion Pharmaceuticals Inc Details

2.3.2 Alexion Pharmaceuticals Inc Major Business

2.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.3.4 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.3.5 Alexion Pharmaceuticals Inc Recent Developments and Future Plans

2.4 Alnylam Pharmaceuticals Inc

2.4.1 Alnylam Pharmaceuticals Inc Details

2.4.2 Alnylam Pharmaceuticals Inc Major Business

2.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.4.4 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.4.5 Alnylam Pharmaceuticals Inc Recent Developments and Future Plans

2.5 Amgen Inc

2.5.1 Amgen Inc Details

2.5.2 Amgen Inc Major Business

2.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.5.4 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.5.5 Amgen Inc Recent Developments and Future Plans

2.6 Apellis Pharmaceuticals Inc

2.6.1 Apellis Pharmaceuticals Inc Details

2.6.2 Apellis Pharmaceuticals Inc Major Business

2.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.6.4 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.6.5 Apellis Pharmaceuticals Inc Recent Developments and Future Plans

2.7 F. Hoffmann-La Roche Ltd

2.7.1 F. Hoffmann-La Roche Ltd Details

2.7.2 F. Hoffmann-La Roche Ltd Major Business

2.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.7.4 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.7.5 F. Hoffmann-La Roche Ltd Recent Developments and Future Plans

2.8 ISU ABXIS Co Ltd

2.8.1 ISU ABXIS Co Ltd Details

2.8.2 ISU ABXIS Co Ltd Major Business

2.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.8.4 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.8.5 ISU ABXIS Co Ltd Recent Developments and Future Plans

2.9 Novartis AG

2.9.1 Novartis AG Details

2.9.2 Novartis AG Major Business

2.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.9.4 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.9.5 Novartis AG Recent Developments and Future Plans

2.10 NovelMed Therapeutics Inc

2.10.1 NovelMed Therapeutics Inc Details

2.10.2 NovelMed Therapeutics Inc Major Business

2.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.10.4 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.10.5 NovelMed Therapeutics Inc Recent Developments and Future Plans

2.11 Omeros Corp

2.11.1 Omeros Corp Details

2.11.2 Omeros Corp Major Business

2.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.11.4 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.11.5 Omeros Corp Recent Developments and Future Plans

2.12 Ra Pharmaceuticals Inc

2.12.1 Ra Pharmaceuticals Inc Details

2.12.2 Ra Pharmaceuticals Inc Major Business

2.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.12.4 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.12.5 Ra Pharmaceuticals Inc Recent Developments and Future Plans

2.13 Regeneron Pharmaceuticals Inc

2.13.1 Regeneron Pharmaceuticals Inc Details

2.13.2 Regeneron Pharmaceuticals Inc Major Business

2.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.13.4 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.13.5 Regeneron Pharmaceuticals Inc Recent Developments and Future Plans

2.14 Regenesance BV

2.14.1 Regenesance BV Details

2.14.2 Regenesance BV Major Business

2.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

2.14.4 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)

2.14.5 Regenesance BV Recent Developments and Future Plans

3 Market Competition, by Players

3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Share by Players (2019, 2020, 2021, and 2022)

3.2 Market Concentration Rate

3.2.1 Top 3 Paroxysmal Nocturnal Hemoglobinuria Treatment Players Market Share in 2021

3.2.2 Top 10 Paroxysmal Nocturnal Hemoglobinuria Treatment Players Market Share in 2021

3.2.3 Market Competition Trend

3.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Players Head Office, Products and Services Provided

3.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Mergers & Acquisitions

3.5 Paroxysmal Nocturnal Hemoglobinuria Treatment New Entrants and Expansion Plans

4 Market Size Segment by Type

4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Market Share by Type (2017-2022)

4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Forecast by Type (2023-2028)

5 Market Size Segment by Application

5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application (2017-2022)

5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Forecast by Application (2023-2028)

6 North America by Country, by Type, and by Application

6.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2028)

6.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2028)

6.3 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country

6.3.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2028)

6.3.2 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

6.3.3 Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

6.3.4 Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

7 Europe by Country, by Type, and by Application

7.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2028)

7.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2028)

7.3 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country

7.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2028)

7.3.2 Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

7.3.3 France Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

7.3.4 United Kingdom Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

7.3.5 Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

7.3.6 Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

8 Asia-Pacific by Region, by Type, and by Application

8.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2028)

8.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2028)

8.3 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region

8.3.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Region (2017-2028)

8.3.2 China Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

8.3.3 Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

8.3.4 South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

8.3.5 India Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

8.3.6 Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

8.3.7 Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

9 South America by Country, by Type, and by Application

9.1 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2028)

9.2 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2028)

9.3 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country

9.3.1 South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2028)

9.3.2 Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

9.3.3 Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

10 Middle East & Africa by Country, by Type, and by Application

10.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2028)

10.2 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2028)

10.3 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Country

10.3.1 Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2028)

10.3.2 Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

10.3.3 Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

10.3.4 UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size and Forecast (2017-2028)

11 Research Findings and Conclusion

12 Appendix

12.1 Methodology

12.2 Research Process and Data Source

12.3 Disclaimer

List of Tables

Table 1. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type, (USD Million), 2017 VS 2021 VS 2028

Table 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application, (USD Million), 2017 VS 2021 VS 2028

Table 3. Global Market Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)

Table 4. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) by Region (2017-2022)

Table 5. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Region (2023-2028)

Table 6. Achillion Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 7. Achillion Pharmaceuticals Inc Major Business

Table 8. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 9. Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 10. Akari Therapeutics Plc Corporate Information, Head Office, and Major Competitors

Table 11. Akari Therapeutics Plc Major Business

Table 12. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 13. Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 14. Alexion Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 15. Alexion Pharmaceuticals Inc Major Business

Table 16. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 17. Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 18. Alnylam Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 19. Alnylam Pharmaceuticals Inc Major Business

Table 20. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 21. Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 22. Amgen Inc Corporate Information, Head Office, and Major Competitors

Table 23. Amgen Inc Major Business

Table 24. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 25. Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 26. Apellis Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 27. Apellis Pharmaceuticals Inc Major Business

Table 28. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 29. Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 30. F. Hoffmann-La Roche Ltd Corporate Information, Head Office, and Major Competitors

Table 31. F. Hoffmann-La Roche Ltd Major Business

Table 32. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 33. F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 34. ISU ABXIS Co Ltd Corporate Information, Head Office, and Major Competitors

Table 35. ISU ABXIS Co Ltd Major Business

Table 36. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 37. ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 38. Novartis AG Corporate Information, Head Office, and Major Competitors

Table 39. Novartis AG Major Business

Table 40. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 41. Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 42. NovelMed Therapeutics Inc Corporate Information, Head Office, and Major Competitors

Table 43. NovelMed Therapeutics Inc Major Business

Table 44. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 45. NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 46. Omeros Corp Corporate Information, Head Office, and Major Competitors

Table 47. Omeros Corp Major Business

Table 48. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 49. Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 50. Ra Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 51. Ra Pharmaceuticals Inc Major Business

Table 52. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 53. Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 54. Regeneron Pharmaceuticals Inc Corporate Information, Head Office, and Major Competitors

Table 55. Regeneron Pharmaceuticals Inc Major Business

Table 56. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 57. Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 58. Regenesance BV Corporate Information, Head Office, and Major Competitors

Table 59. Regenesance BV Major Business

Table 60. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Product and Solutions

Table 61. Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)

Table 62. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)

Table 63. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Players (2019, 2020, 2021, and 2022)

Table 64. Breakdown of Paroxysmal Nocturnal Hemoglobinuria Treatment by Company Type (Tier 1, Tier 2 and Tier 3)

Table 65. Paroxysmal Nocturnal Hemoglobinuria Treatment Players Head Office, Products and Services Provided

Table 66. Paroxysmal Nocturnal Hemoglobinuria Treatment Mergers & Acquisitions in the Past Five Years

Table 67. Paroxysmal Nocturnal Hemoglobinuria Treatment New Entrants and Expansion Plans

Table 68. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) by Type (2017-2022)

Table 69. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Type (2017-2022)

Table 70. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Forecast by Type (2023-2028)

Table 71. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2022)

Table 72. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Forecast by Application (2023-2028)

Table 73. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2022) & (USD Million)

Table 74. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2023-2028) & (USD Million)

Table 75. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2022) & (USD Million)

Table 76. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2023-2028) & (USD Million)

Table 77. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2022) & (USD Million)

Table 78. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2023-2028) & (USD Million)

Table 79. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2022) & (USD Million)

Table 80. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2023-2028) & (USD Million)

Table 81. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2022) & (USD Million)

Table 82. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2023-2028) & (USD Million)

Table 83. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2022) & (USD Million)

Table 84. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2023-2028) & (USD Million)

Table 85. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2022) & (USD Million)

Table 86. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2023-2028) & (USD Million)

Table 87. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2022) & (USD Million)

Table 88. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2023-2028) & (USD Million)

Table 89. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Region (2017-2022) & (USD Million)

Table 90. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Region (2023-2028) & (USD Million)

Table 91. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2022) & (USD Million)

Table 92. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2023-2028) & (USD Million)

Table 93. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2022) & (USD Million)

Table 94. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2023-2028) & (USD Million)

Table 95. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2022) & (USD Million)

Table 96. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2023-2028) & (USD Million)

Table 97. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2017-2022) & (USD Million)

Table 98. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Type (2023-2028) & (USD Million)

Table 99. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2017-2022) & (USD Million)

Table 100. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Application (2023-2028) & (USD Million)

Table 101. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2017-2022) & (USD Million)

Table 102. Middle East & Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Country (2023-2028) & (USD Million)

List of Figures

Figure 1. Paroxysmal Nocturnal Hemoglobinuria Treatment Picture

Figure 2. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Type in 2021

Figure 3. ACH-4471

Figure 4. ALN-CC5

Figure 5. ALXN-1210

Figure 6. AMY-101

Figure 7. APL-2

Figure 8. Others

Figure 9. Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Application in 2021

Figure 10. Hospital Picture

Figure 11. Clinic Picture

Figure 12. Others Picture

Figure 13. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, (USD Million): 2017 VS 2021 VS 2028

Figure 14. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Forecast (2017-2028) & (USD Million)

Figure 15. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Region (2017-2028)

Figure 16. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Region in 2021

Figure 17. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 18. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 19. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 20. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 21. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue (USD Million) and Growth Rate (2017-2028)

Figure 22. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers

Figure 23. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints

Figure 24. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Trends

Figure 25. Achillion Pharmaceuticals Inc Recent Developments and Future Plans

Figure 26. Akari Therapeutics Plc Recent Developments and Future Plans

Figure 27. Alexion Pharmaceuticals Inc Recent Developments and Future Plans

Figure 28. Alnylam Pharmaceuticals Inc Recent Developments and Future Plans

Figure 29. Amgen Inc Recent Developments and Future Plans

Figure 30. Apellis Pharmaceuticals Inc Recent Developments and Future Plans

Figure 31. F. Hoffmann-La Roche Ltd Recent Developments and Future Plans

Figure 32. ISU ABXIS Co Ltd Recent Developments and Future Plans

Figure 33. Novartis AG Recent Developments and Future Plans

Figure 34. NovelMed Therapeutics Inc Recent Developments and Future Plans

Figure 35. Omeros Corp Recent Developments and Future Plans

Figure 36. Ra Pharmaceuticals Inc Recent Developments and Future Plans

Figure 37. Regeneron Pharmaceuticals Inc Recent Developments and Future Plans

Figure 38. Regenesance BV Recent Developments and Future Plans

Figure 39. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Players in 2021

Figure 40. Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021

Figure 41. Global Top 3 Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share in 2021

Figure 42. Global Top 10 Players Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share in 2021

Figure 43. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)

Figure 44. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Type in 2021

Figure 45. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share Forecast by Type (2023-2028)

Figure 46. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Share by Application in 2021

Figure 47. Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share Forecast by Application (2023-2028)

Figure 48. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Type (2017-2028)

Figure 49. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Application (2017-2028)

Figure 50. North America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Country (2017-2028)

Figure 51. United States Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 52. Canada Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 53. Mexico Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 54. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Type (2017-2028)

Figure 55. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Application (2017-2028)

Figure 56. Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Country (2017-2028)

Figure 57. Germany Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 58. France Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 59. United Kingdom Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 60. Russia Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 61. Italy Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 62. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Type (2017-2028)

Figure 63. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Application (2017-2028)

Figure 64. Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Region (2017-2028)

Figure 65. China Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 66. Japan Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 67. South Korea Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 68. India Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 69. Southeast Asia Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 70. Australia Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 71. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Type (2017-2028)

Figure 72. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Application (2017-2028)

Figure 73. South America Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Country (2017-2028)

Figure 74. Brazil Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 75. Argentina Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 76. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Type (2017-2028)

Figure 77. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Sales Market Share by Application (2017-2028)

Figure 78. Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue Market Share by Country (2017-2028)

Figure 79. Turkey Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 80. Saudi Arabia Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 81. UAE Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue and Growth Rate (2017-2028) & (USD Million)

Figure 82. Methodology

Figure 83. Research Process and Data Source

shopping_cart License Type

Buy Now

email Quick Contact

+1

tag_faces Our Clients

help Need Help?

Please contact directly on our US and India numbers

+1-201-465-4211

Please feel free to write an email to us or to use our electronic ticketing system.

sales@marketquest.biz